RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability
View / Open Files
Authors
Chen, Edwin
Ahn, Jong Sook
Sykes, David B
Breyfogle, Lawrence J
Godfrey, Anna L
Nangalia, Jyoti
Ko, Amy
DeAngelo, Daniel J
Mullally, Ann
Publication Date
2015-12-10Alternative Title
RECQL5 promotes genome stability in MPN
RECQL5 suppresses JAK2V617F-induced replication stress and genomic instability
Journal Title
Cell Reports
ISSN
2211-1247
Publisher
Elsevier
Volume
13
Pages
2345-2352
Language
English
Type
Article
Metadata
Show full item recordCitation
Chen, E., Ahn, J. S., Sykes, D. B., Breyfogle, L. J., Godfrey, A. L., Nangalia, J., Ko, A., et al. (2015). RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Reports, 13 2345-2352. https://doi.org/10.1016/j.celrep.2015.11.037
Abstract
JAK2V617F is the most common oncogenic lesion in patients with myeloproliferative neoplasms (MPN). Despite the ability of JAK2V617F to instigate DNA damage in vitro, MPN is nevertheless characterized by genomic stability. In this study, we address this paradox by identifying the DNA helicase RECQL5 as a suppressor of genomic instability in MPN. We report increased RECQL5 expression in JAK2V617F-expressing cells and demonstrate that RECQL5 is required to counteract JAK2V617F-induced replication stress. Moreover, RECQL5 depletion sensitizes JAK2V617F-mutant cells to hydroxyurea (HU), a pharmacological inducer of replication stress and the most common treatment for MPN. Using single-fiber chromosome combing we show that RECQL5 depletion in JAK2V617F-mutant cells impairs replication dynamics following HU treatment, resulting in increased double-stranded breaks and apoptosis. Cumulatively, these findings identify RECQL5 as a critical regulator of genome stability in MPN and demonstrate that replication stress-associated cytotoxicity can be amplified specifically in JAK2V617F-mutant cells through RECQL5-targeted synthetic lethality.
Sponsorship
This work was supported by the NIH (K08 HL109734 to AM) and the MPN Research Foundation (AM). A.M. receives support from the Jeanne D. Housman Fund for Research on Myeloproliferative Disorders and is a recipient of a Damon Runyon clinical investigator award. EC is a recipient of a Lady Tata Memorial Trust Award.
Funder references
WELLCOME TRUST (104710/Z/14/Z)
Identifiers
External DOI: https://doi.org/10.1016/j.celrep.2015.11.037
This record's URL: https://www.repository.cam.ac.uk/handle/1810/252434
Rights
Creative Commons Attribution 4.0 International License
Licence URL: http://creativecommons.org/licenses/by/4.0/


